AAHP Continuing Education Course 2

AAHP will host Continuing Education Courses at the 2024 IRPA 16th International Congress/69th HPS Annual Meeting. The sessions will be held in Orlando, Florida on Saturday, July 6, 2024.

Members and non-members are welcome.


2024 AAHP Continuing Education Courses

Any personal or professional opinions presented within these courses reflect those of the presenters, and not necessarily those of the Academy.

Course 2: 4-hours (8 CECs)

The Scientific, Clinical, and Regulatory Basis of Theranostics

8:00 am - 12:00 pm, Orlando, FL local time (Eastern Time)

Presenter Names

Gregory D. Espenan

Course Description

The field of theranostics has expanded dramatically over the last 30 years and provides a two-pronged approach to diagnosing and treating cancers through the use of radiopharmaceuticals. A diagnostic drug first identifies if the patient is a good candidate for treatment then, if the patient demonstrates good uptake, a therapeutic drug is administered to treat their cancer. These drugs selectively bind to specific cell types in the body to provide targeted therapy and their use has expanded to include the treatment of cancer types which previously had no effective therapies available. This presentation will discuss the process of producing these radiopharmaceuticals and the pathway necessary to achieve regulatory approval. This presentation will cover clinical action and effectiveness, the methods needed to handle radioactive patients, the methods for determining organ burdens and patient dosimetry, and the future of radiopharmaceutical therapy. 

  • Part 1 Drug Development: Pre-clinical work, testing in cell lines and animals, determining method of action, and initial dosimetry will be discussed. FDA applications for approval to test in humans will be outlined. The phases of clinical trials and what each phase accomplishes, in patient dosimetry, unexpected side effects and radioactive patient management are topics in this section.
  • Part 2 Current Drugs: Ga-68 dotatate, Pb-212 dotatate, Ac-225 dotatate, Ga-68-PSMA, Lu-177 PSMA, Zr-89 CAIX, and Lu-177 TLX250 will be discussed. Imaging agents and therapies will be discussed as a number of these drugs are not in wide use.

 

Location and Contact Info


Rosen Shingle Creek

9939 Universal Blvd
Orlando, FL 32819
 

When
July 6th, 2024 from  8:00 AM to 10:00 AM
Event Fee(s)
Course 2: The Scientific, Clinical, and Regulatory Basis of Theranostics $200.00